Barinthus Biotherapeutics’ (BRNS) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Barinthus Biotherapeutics (NASDAQ:BRNS) in a report issued on Friday, Benzinga reports. HC Wainwright currently has a $8.00 price target on the stock.

Separately, William Blair reissued an outperform rating on shares of Barinthus Biotherapeutics in a research report on Monday, January 8th.

Barinthus Biotherapeutics Stock Down 6.8 %

BRNS stock opened at $2.53 on Friday. The stock has a market cap of $98.27 million, a P/E ratio of -1.32 and a beta of -0.52. The business has a 50-day moving average of $2.69. Barinthus Biotherapeutics has a 12 month low of $1.64 and a 12 month high of $5.10.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its earnings results on Wednesday, March 20th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.10. As a group, analysts predict that Barinthus Biotherapeutics will post -2.6 earnings per share for the current fiscal year.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.